Survey on Pharmacy professionals views of thromboprophylaxis in people receiving SACT

Pharmacy professionals views of thromboprophylaxis in people receiving systemic anticancer therapy (SACT) – 5 min survey to inform the development of a clinical trial

Venous thromboembolism (VTE) is a common complication in patients with malignancy, including lung cancer, and is a leading cause of death and morbidity in these patients. However, the role of direct oral anticoagulants (DOACs) for thromboprophylaxis in patients with lung cancer remains uncertain and requires further investigation.

We would be grateful if you could complete a short survey (link below) designed to find out more about pharmacist and pharmacy technician views of this area. Your responses will inform the development of a clinical trial exploring the effectiveness of oral thromboprophylaxis at reducing the rate of venous thromboembolism in people receiving systemic anti-cancer therapy for lung cancer.

https://cardiff.onlinesurveys.ac.uk/antler-trial-lung-cancer-survey-for-pharmacy-professional

This should take no longer than 5 minutes to complete, the deadline for completion is 31-Dec-2023.

We hope BOPA members can be further involved in the development and delivery of the clinical trial and we will keep you updated on progress and opportunities.

Thank you for your help,

Prof Alastair Greystoke, Consultant Oncologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Dr Kate Musgrave, Consultant Haematologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust

Emma Groves, Lead Pharmacist – Genomic Medicine, NHS North East and Yorkshire Genomic Medicine Service Alliance